CVS Health EVP sells 69,551 shares

CVS Health executive vice president and Chief Experience & Technology Officer Tilak Mandadi sold 69,551 shares of CVS common stock in an open-market transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CVS Health executive vice president and Chief Experience & Technology Officer Tilak Mandadi sold 69,551 shares of CVS common stock in an open-market transaction. The shares were sold at an average price of about $89.58 per share, with prices ranging between $89.30 and $89.81. After this sale, Mandadi directly holds 10,133 CVS shares.

Insider Trade Summary

Net Seller: 69,551 shares

Net Sell 1 txn

Insider Mandadi Tilak

Role EVP, Chief Exp & Tech Officer

Sold 69,551 shs ($6.23M)

Type	Security	Shares	Price	Value
Sale	Common Stock	69,551	$89.58	$6.23M

Holdings After Transaction: Common Stock — 10,133 shares (Direct)

Footnotes (1)

F1. All shares sold at an Average price between $89.30 and $89.81.

Key Figures

Shares sold: 69,551 shares Sale price per share: $89.58 per share Post-sale holdings: 10,133 shares +2 more

5 metrics

Shares sold 69,551 shares Open-market sale of CVS common stock

Sale price per share $89.58 per share Reported transaction price for the sale

Post-sale holdings 10,133 shares Directly owned CVS shares after transaction

Price range $89.30–$89.81 Footnote: average sale price range

Transaction date 2026-05-08 Date of reported share sale

Key Terms

open-market sale, Common Stock, Form 4, Average price

4 terms

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Average price financial

"All shares sold at an Average price between $89.30 and $89.81"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CVS (CVS) report for Tilak Mandadi?

CVS reported that EVP and Chief Experience & Technology Officer Tilak Mandadi sold 69,551 shares of CVS common stock in an open-market transaction. This filing shows the scale, pricing, and resulting ownership after the sale.

How many CVS shares did Tilak Mandadi sell and at what price?

Tilak Mandadi sold 69,551 CVS common shares at an average price of about $89.58 per share. A footnote explains the trades occurred between $89.30 and $89.81, reflecting typical execution across multiple transactions.

How many CVS shares does Tilak Mandadi hold after this sale?

After the reported sale, Tilak Mandadi directly holds 10,133 CVS common shares. This figure comes from the post-transaction ownership reported in the Form 4 and helps show the remaining equity stake disclosed in this filing.

Was Tilak Mandadi’s CVS stock sale an open-market transaction?

Yes. The Form 4 classifies the transaction as an open-market sale of common stock, coded as “S.” This code indicates a sale in the market or a private transaction rather than a grant, option exercise, or tax-withholding event.

Did the CVS Form 4 disclose any option exercises or derivatives for Tilak Mandadi?

No derivative transactions are listed for Tilak Mandadi in this Form 4. The derivativeSummary section is empty, and the transactionSummary shows zero derivative exercises, indicating only a common-stock sale was reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/11/2026 - 05:27 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mandadi Tilak

(Last)

(First)

(Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET

RHODE ISLAND

02895

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Exp & Tech Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/08/2026		S		69,551	D	$89.58⁽¹⁾	10,133	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. All shares sold at an Average price between $89.30 and $89.81.

	/s/ Tilak Mandadi	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR